OliX Pharmaceuticals Secures KRW 110 Billion Investment from BOLD, L’Oréal Corporate Venture Capital Fund, and Weiss, U.S. Hedge Fund

SEOUL, South Korea--(BUSINESS WIRE)-- #BOLD--OliX, an RNAi developer, secures a KRW 110 billion biotech investment from BOLD and Weiss Asset Management LP.